Oncotelic Therapeutics Highlights Two Years of Clinical Progress Across Oncology and Rare Disease Programs

Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a clinical-stage biopharmaceutical company, has announced a comprehensive summary of major accomplishments achieved over the past two years across its oncology and rare disease programs. The progress spans multiple late-stage therapeutic candidates, including OT-101, which is now in Phase 3 clinical trials for pancreatic cancer with additional applications in ARDS/COVID-19. Another key asset, OXi4503, is advancing from Phase 2 in acute myeloid leukemia and myelodysplastic syndromes toward pivotal Phase 3 design.

The company's portfolio extends beyond these programs to include CA4P/Fosbretabulin, AL-101 for Parkinson's disease and sexual dysfunctions, and AL-102 in discovery phase for Alzheimer's disease. Additionally, Oncotelic is developing pediatric rare disease programs with potential Priority Review Vouchers and advancing a nanomedicine pipeline with several 505(b)(2) drug candidates. CEO Dr. Vuong Trieu emphasized that this progress strengthens the company's position as a late-stage biotechnology firm with broad value creation potential across multi-billion-dollar markets characterized by high unmet medical need.

Beyond its directly owned and developed drug pipeline, Oncotelic benefits from the extensive intellectual property portfolio created by Dr. Trieu, who has filed over 150 patent applications and holds 39 issued U.S. patents. The company also maintains strategic partnerships through joint ventures, including owning 45% of GMP Bio, which is advancing its own pipeline of drug candidates that complement Oncotelic's strategic position in oncology and rare disease therapeutics. Additional information about the company's developments can be found at https://ibn.fm/OTLC.

The implications of these clinical advancements are significant for patients, healthcare providers, and the biotechnology industry. The progression of OT-101 to Phase 3 trials for pancreatic cancer addresses a critical unmet need in oncology, as pancreatic cancer remains one of the most challenging cancers to treat with limited therapeutic options. Similarly, the advancement of OXi4503 for AML/MDS represents potential breakthroughs in blood cancer treatments. The diverse pipeline spanning multiple disease areas demonstrates Oncotelic's strategic approach to targeting high-value markets with substantial medical needs.

For the biotechnology sector, Oncotelic's progress exemplifies the potential for clinical-stage companies to advance multiple programs simultaneously while maintaining focus on both oncology and rare diseases. The company's intellectual property foundation and joint venture structure provide a model for leveraging external innovation while maintaining strategic control. Investors and industry observers can track further developments through the company's newsroom at https://ibn.fm/jH9C1, which provides ongoing updates about the company's clinical progress and corporate developments.